 |
| Global Gene And Cell Therapies Targeting CNS Disorders Market Size |
Gene and cell therapies hold immense potential for treating complex CNS disorders by providing long-term functional improvements. These therapies involve modifying autologous cells, delivering them to the specific sites in the brain, and enabling them to secrete therapeutic proteins or exert trophic and immunomodulatory effects.
The global
Gene and Cell Therapies Targeting CNS Disorders Market is estimated to be
valued at US$ 8.2 Bn in 2023 and is expected to exhibit a CAGR of 11% over the
forecast period 2023 to 2030, as highlighted in a new report published by
Coherent Market Insights.
Market key trends:
The growing integration of emerging gene-based therapies such as CAR T-cell
therapy, gene therapy, and gene editing is accelerating the growth of this
market. These novel therapies are enabling more targeted and personalized
treatment approaches that are transforming the current treatment paradigm of
several CNS disorders. For instance, gene therapy involves introducing genetic
material into target cells of patients to compensate for abnormal genes or to
produce protective or therapeutic substances. Companies are conducting various
clinical trials on gene therapies for diverse CNS indications like Alzheimer's,
Parkinson's, motor neuron diseases, and retinal disorders. This rising
integration of advanced gene-based modalities is expected to significantly
expand treatment options and drive the growth of this market over the forecast
period.
Segment Analysis: For the Gene and Cell Therapies Targeting CNS Disorders
Market, the dominating sub-segment is Cell Therapies. This is because Cell
therapies have proven highly promising for the treatment of various CNS
disorders. These therapies involve transplanting human cells into the brain and
spinal cord with the aim to replace damaged or dead cells. The cells aim to
re-establish lost connections in the central nervous system.
Key Takeaways:
Global
Gene And Cell Therapies Targeting CNS Disorders Market Size is expected
to witness high growth. Regional analysis: North America region currently
dominates the market due to high healthcare spending and presence of key market
players. The USA is the fastest growing nation in the region due to presence of
advanced healthcare infrastructure and high new product adoption rate. However,
Asia Pacific region is expected to witness highest CAGR over the forecast
period with China and India being the major contributors. Growing geriatric
population, improving healthcare facilities and rising medical tourism are
driving the regional market growth.
Key players: Key players operating in the Gene and Cell Therapies Targeting CNS
Disorders Market are Sophion Bioscience A/S, Nanion Technologies GmbH, NeoBiosystems,
Inc., Multi Channel Systems MCS GmbH, Fluxion Biosciences, Molecular Devices,
LLC, Scitech Korea Inc., and HEKA Elektronik GmbH. Sophion Bioscience A/S is a
leading player in the market owing to its strong portfolio of cellular analysis
instruments for ion channel and transporter drug discovery. Nanion Technologies
GmbH specializes in the voltage-clamp technologies.
Discover More@ https://www.ukwebwire.com/global-gene-and-cell-therapies-targeting-cns-disorders-market-scope/